Project Grant R01CA315487
Award Date 8/3/26
Completion Date 7/31/31
Dollars Obligated $645K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $671,740 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define biomarkers and overcome resistance to DLL3-targeting immune therapies in small cell lung cancer. The research focuses on understanding tumor-intrinsic and immune-related mechanisms of response and resistance to delta-like ligand 3 (DLL3)-targeting T-cell engagers, particularly following the FDA approval of...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Texas Health Science Center at Houston $635,948 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate phospholipase D1 (PLD1) and transferrin receptor 1 (TFR1) as therapeutic targets in chromosome 3q-amplified non-small cell lung cancer. The project will define the mechanisms by which PLD1 promotes NSCLC progression and tumor microenvironment...
- The National Institutes of Health National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $680,129 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop drug-loaded degradable biopolymeric scaffolds for augmenting preoperative liver growth. The award funds development of three integrated components: a rat tumor model with cirrhosis background to serve as a clinically translatable animal model; resorbable polymeric scaffolds with...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $192,224 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research on secreted peptides as biomarkers and effectors of neuroendocrine transformation in lung cancer. The funded work investigates pulmonary neuroendocrine cell (PNEC) biology and the histologic transformation of lung adenocarcinoma to small cell lung cancer. The research employs a genetically engineered...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $621,632 on June 17, 2026, under the Cancer Treatment Research program (CFDA 93.395) to elucidate the molecular and metabolic mechanisms underlying disulfidptosis and therapeutically target this form of regulated cell death in SLC7A11-high cancers. The research employs human cancer cell lines and integrated cell-based molecular analyses including metabolomics, proteomics, CRISPR screening, and biochemical...
- The National Cancer Institute awarded MD Anderson Cancer Center $669,540 on July 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to elucidate the roles of the CD24 ligand in early lung cancer development, immune evasion, and response to KRAS-targeted therapy. The research investigates CD24 signaling in KRAS-mutant lung adenocarcinomas (KM-LUADs), which account for approximately 30 percent of lung adenocarcinomas in lifetime smokers. Preliminary findings indicate CD24 elevation...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $706,739 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to unravel the molecular mechanisms of immunotherapy-associated myocarditis. The research investigates how immune checkpoint inhibitors, which enhance anti-tumor immune responses in cancer treatment, trigger myocarditis—inflammation of the heart that carries mortality rates up to 50 percent. The project uses mouse models...
- This $762,992 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research by the University of Texas MD Anderson Cancer Center to map and predict therapy resistance in small cell lung cancer (SCLC) using liquid biopsies. The 3-year award, effective July 1, 2024, will enable MD Anderson to conduct personalized analyses to better understand how SCLC tumors evolve and become resistant to treatment. This work aims to...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $421,685 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize clonal evolution and immune dysregulation in acute myeloid leukemia patients treated with venetoclax and azacitidine following allogeneic stem cell transplantation. The research addresses post-transplant AML relapse mechanisms by pursuing two primary aims: characterizing the mutational landscape at diagnosis,...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $667,282 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to develop and test dissemination strategies for lung cancer screening education and counseling delivered through existing state tobacco quitlines. The project compares a low-touch strategy (text/email educational materials alone) against a high-touch strategy in which tobacco treatment specialists within...